Mesothelin gene expression and promoter methylation/hypomethylation in gynecological tumors

Purpose: Mesothelin is a cell surface glycoprotein that is present on normal mesothelial cells and overexpressed in severalcancers. In this study, we investigated the methylation/hypomethylation status in the promoter region of the mesothelin gene in gynecological tumors. Methods: Forty-four ovarian tumor specimens and 16 cases of uterine endometrial carcinoma, and normal tissue specimens were used. Monoclonal antibody (5B2) was employed for the immunohistochemical analysis. The methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) technique was used to quantify the methylation/hypomethylation status at 20 CpG sites in the mesothelin promoter region. Results: Mesothelin was expressed in 100% of serous cystadenocarcinoma and 100% of serous borderline tumor of the ovary. None of the germ cell tumors and sexcord-stromal tumors was immunoreactive. Fifty percent of endometrial carcinoma was immunoreactive for mesothelin. The average methylation of CpG sites in ovarian tumors ranged from 6-56% (median: 31%) in mesothelin-positive and 13-79% (median: 43%) in mesothelin-negative samples. In endometrial tumors, the average methylation ranged from 5-52% (median: 28%) in mesothlin-positive and from 15-67% (median: 22%) in mesothlinnegative samples. A correlation was found between mesothelin expression and the average methylation/hypomethylation status as well as methylation/hypomethylation status at four of 20 CpG sites in ovarian samples. No correlation was found in endometrial samples. Conclusion: We detected diverse levels of methylation/hypomethylation at CpG sites in the mesothelin promoter region in ovarian and endometrial tumors. We speculate that, although methylation/hypomethylation changes may affect its transcription, other mechanisms may synergically operate in tissue-specific expression and tumor-related mesothelin overexpression.

Mesothelin; Overexpression; Gynecological tumors; Promoter methylation; Hypomethylation.

[1] Chang K., Pastan I.: “Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian car-cinoma (OVCAR-3) cell line”. Int. J. Cancer, 1994, 57, 90.

[2] Hassan R., Bera T., Pastan I.: “Mesothelin: a new target for immuno therapy”. Clin. Cancer Res., 2004, 10 (12 Pt 1), 3937.

[3] Chang K., Pastan I., Willingham M.C.: “Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium”. Int. J. Cancer, 1992, 50, 373.

[4] Cao D., Ji H., Ronnett B.M. “Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary”. Int. J. Gynecol. Pathol., 2005, 24, 67.

[5] Chang K., Pastan I., Willingham M.C. “Frequent expression of the tumor antigen CAK1 in squamouscell carcinomas”. Int. J. Cancer, 1992, 51, 548.

[6] Dainty L.A., Risinger J.I., Morrison C., Chandramouli G.V., Bidus M. A., Zahn C., et al.: “Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma”. Gynecol. Oncol., 2007, 105, 563.

[7] Frierson H.F., Jr., Moskaluk C.A., Powell S.M., Zhang H., Cerilli L. A., Stoler M.H., et al.: “Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas”. Hum. Pathol., 2003, 34, 605.

[8] Hassan R., Laszik Z.G., Lerner M., Raffeld M., Postier R., Brackett D.: “Mesothelin is overexpressed in pancreaticobiliary adeno-carcinomas but not in normal pancreas and chronic pancreatitis”. Am. J. Clin. Pathol., 2005, 124, 838.

[9] Hassan R., Remaley A.T., Sampson M.L., Zhang J., Cox D.D., Pingpank J. et al.: “Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer”. Clin. Cancer Res., 2006, 12, 447.

[10] Ho M., Bera T.K., Willingham M.C., Onda M., Hassan R., FitzGerald D., et al. “Mesothelin expression in human lung cancer”. Clin. Cancer Res., 2007, 13, 1571.

[11] Ho M., Hassan R., Zhang J., Wang Q.C., Onda M., Bera T. et al.: “Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients”. Clin. Cancer Res., 2005, 11, 3814.

[12] Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D. D., Rosenshein N.B. et al.: “Largescale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer”. Cancer Res., 2000, 60, 6281.

[13] Ordonez N.G. “Application of mesothelin immunostaining in tumor diagnosis”. Am. J. Surg. Pathol., 2003, 27, 1418.

[14] Robinson B.W., Creaney J., Lake R., Nowak A., Musk A.W., de Klerk N. et al.: “Mesothelin-family proteins and diagnosis of mesothelioma”. Lancet, 2003, 362, 1612.

[15] Shiomi K., Hagiwara Y., Sonoue K., Segawa T., Miyashita K., Maeda M. et al.: “Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma”. Clin. Cancer Res., 2008, 14, 1431.

[16] Robinson B.W., Creaney J., Lake R., Nowak A., Musk A.W., de Klerk N. et al.: “Soluble mesothelin-related proteina blood test for mesothelioma”. Lung Cancer, 2005, 49 (suppl. 1.), S109.

[17] Sato N., Maitra A., Fukushima N., van Heek N.T., Matsubayashi H., Iacobuzio-Donahue C.A. et al.: “Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma”. Cancer Res., 2003, 63, 4158.

[18] Hucl T., Brody J.R., Gallmeier E., Iacobuzio-Donahue C.A., Far-rance I.K., Kern S.E.: “High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif”. Cancer Res., 2007, 67, 9055.

[19] Kuppuswamy M.N., Hoffmann J.W., Kasper C.K., Spitzer S.G., Groce S.L., Bajaj S.P.: “Single nucleotide primer extension to detect genetic diseases: experimental application to hemophilia B (factor IX) and cystic fibrosis genes”. Proc. Natl. Acad. Sci. U S A, 1991, 88, 1143.

[20] Gonzalgo M.L., Jones P.A.: “Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE)”. Nucleic Acids Res., 1997, 25, 2529.

[21] Gonzalgo M.L., Liang G.: “Methylation-sensitive singlenucleotide primer extension (Ms-SNuPE) for quantitative measurement of DNA methylation”. Nat. Protoc., 2007, 2, 1931.

[22] Chang K., Pai L.H., Batra J.K., Pastan I., Willingham M.C.: “Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium”. Cancer Res., 1992, 52, 181.

[24] Hassan R., Kreitman R.J., Pastan I., Willingham M.C.: “Localization of mesothelin in epithelial ovarian cancer”. Appl. Immuno -histochem. Mol. Morphol., 2005, 13, 243.

[25] Hellstrom I., Friedman E., Verch T., Yang Y., Korach J., Jaffar J. et al.: “Antimesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients”. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 1520.

[26] Yen M.J., Hsu C.Y., Mao T.L., Wu T.C., Roden R., Wang T.L. et al.: “Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma”. Clin. Cancer Res., 2006, 12(3 Pt 1), 827.

[27] Rump A., Morikawa Y., Tanaka M., Minami S., Umesaki N., Takeuchi M. et al.: “Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion”. J. Biol. Chem., 2004, 279, 9190.

[28] Chang K., Pastan I. “Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers”. Proc. Natl. Acad. Sci. U S A, 1996, 93, 136.

[29] Hellstrom I., Raycraft J., Kanan S., Sardesai N.Y., Verch T., Yang Y. et al.: “Mesothelin variant 1 is released from tumor cells as a diagnostic marker”. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 1014.

[30] Muminova Z.E., Strong T.V., Shaw D.R.: “Characterization of human mesothelin transcripts in ovarian and pancreatic cancer”. BMC Cancer, 2004, 4, 19.

[31] Scholler N., Fu N., Yang Y., Ye Z., Goodman G.E., Hellstrom K.E. et al.: “Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma”. Proc. Natl. Acad. Sci. U S A, 1999, 96, 11531.

[32] Urwin D., Lake R.A. “Structure of the Mesothelin/MPF gene and characterization of its promoter”. Mol. Cell Biol. Res. Commun., 2000, 3, 26.

[33] Hassan R., Ebel W., Routhier E.L., Patel R., Kline J.B., Zhang J. et al.: “Preclinical evaluation of MORAb-009, a chimeric antibody tar-geting tumor-associated mesothelin”. Cancer Immun., 2007, 7, 20.